Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes?: A risk-benefit critique in 2013

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2013-08, Vol.36 (8), p.S155-S161
Hauptverfasser:	SCHERNTHANER, Guntram, CURRIE, Craig J, SCHERNTHANER, Gerit-Holger
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Biomarkers - blood Cardiovascular Diseases - blood Cardiovascular Diseases - epidemiology Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Cholesterol Development and progression Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Diabetes Therapy Diabetes. Impaired glucose tolerance Drug therapy Drug-Related Side Effects and Adverse Reactions - epidemiology Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Humans Hypertension Hypoglycemia - chemically induced Hypoglycemia - epidemiology Hypoglycemia - physiopathology Hypoglycemic agents Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Medical sciences Metabolic diseases Miscellaneous Pharmaceutical industry Public health. Hygiene Public health. Hygiene-occupational medicine Risk Assessment Risk Factors Thiazolidinediones - adverse effects Thiazolidinediones - therapeutic use Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!